Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Started: Tango-Cash, 23 May 2024 12:32
Last post: H2Nick, 23 May 2024 15:06
Looks like expected P/E for 2024 around 7 using low end profit estimate.
134,887,108 shares (from todays "Transaction in Own Shares" RNS)
Low end profit $330M
Projected EPS 2.45 USD
SP 13.66 GBP
so 17.36 USD using ex-rate 1.27113
So P/E ~7.1
Less if profits higher.
(More if they get fined again... Fingers crossed they don't !!!)
Very strong SP move after this update. This together with upcoming primary listing move to USA should be major catalysts over the coming weeks. Share buyback also continuing into August.
Finally we have some clarity from the Board with full year 2024 guidance reaffirmed and 18% YOY revenues exceeded.
Good swing upwards following the RNS which was delivered at 12:00pm only 30 mins ago.
Let's hope we get back to the 1700s over the next couple of weeks. No justifiable reason it shouldn't.
GLA LTH
Started: BetterX, 23 May 2024 14:22
Last post: BetterX, 23 May 2024 14:22
GM just confirmed "We expect the transfer of the primary listing will become effective on Thursday June 27, 2024."
Very strong support for this move as one would expect given that the bulk of sales currently comes from USA.
Started: BetterX, 16 May 2024 17:00
Last post: BetterX, 16 May 2024 17:00
Next Thursday when GM takes place. Should be a formality to get approval.
Started: Baz-Kingsy, 15 May 2024 16:48
Last post: Baz-Kingsy, 16 May 2024 11:02
Relentless R*A*P*E of the share price continues. Absolutely disgusting management corruption and manipulation of sp.
I understand your sentiments Baz but I do believe there will be an upside soon.
I can't think why thd Nasdaq full listing is causing a continuous downward spiral.
The management team need to pull out their sweaty fingers and buck up their ideas.
The crash from £17.90 in April (yes only 1 month ago!) is ridiculous and the management sell off of their (free) shares truly shocking.
Come on Indv reverse this crash.
GLA LTH.
£13.85 close. Shockingly corrupt practices continue by management and MMs dragging the price lower without justification. Stupid b*s*t*r,*d*s I'm out after taking a massive loss from £16.50 only 4 weeks ago. Go to h*e*l*l.
Started: BetterX, 3 May 2024 15:00
Last post: BetterX, 3 May 2024 15:00
How long before INDV is purchased by big pharma? Also share buyback is due to continue until August 2024.
Started: Tango-Cash, 3 May 2024 13:09
Last post: Tango-Cash, 3 May 2024 13:09
FTSE 250
Deutsche Bank initiates Indivior with 'buy' - target 2,350 pence
( PLENTY OF UPSIDE EXPECTED HERE)
Started: dmkingy, 29 Apr 2024 09:13
Last post: idkmybffjill, 30 Apr 2024 07:37
One has nothing to do with the other.
Interesting that the directors sold shares at £17 and the SP drops to under £14!🤔
Started: Tango-Cash, 25 Apr 2024 10:44
Last post: mythyaar, 25 Apr 2024 15:04
I wasn't as energised as I usually am by the presentation. Looks like they're flatlining somewhat. Mitigating factor I guess being the cyber attack which impacted recent revenues. Let's hope that is the reason.
Positives: sublocade still growing and only a small proportion of the market. Sales team fully recruited and resourced so no additional expenses there. They ve got a real foothold now in US market, no doubting that. Dental claim not that big of a deal, reading between the lines. And full steam ahead for shareholder vote next month with view to main US listing in June.
Revenue growth much worse than expected due to those one time factors they mentioned
Excellent quarterly results but unexplainable drop in sp this morning!
...For the three months to March 31, Indivior reported net revenue of USD284 million, up 12% from USD253 million a year prior.
Net income rose 7% to USD47 million from USD44 million, while pretax profit rose 8.6% to USD63 million from USD58 million.
Started: BetterX, 1 Mar 2024 16:25
Last post: Tango-Cash, 12 Mar 2024 09:35
Jefferies raises Indivior price target to 2,390 (2,165) pence - 'buy' (12 March 2024)
More good news!
I would not want this taken over. They’ll steal it at a low price vs. where it can be on its own.
Nice 7% rise on Wall Street today, taking the weekend price up to $23, or £18.17.
SP still well behind the curve based on last results. Broker upgrades to come together with share buy-backs until April & a move to USA. I would also throw in takeover speculation as big pharma circles this relative minnow.
Started: Tango-Cash, 12 Mar 2024 08:28
Last post: Tango-Cash, 12 Mar 2024 08:31
RICHMOND, Va. - Indivior PLC (LSE/Nasdaq: LON:INDV) has announced the results of a pharmacodynamic study indicating that its drug OPVEE® can quickly reverse opioid-induced respiratory depression, a major cause of death in opioid overdoses. The study, comparing intranasal nalmefene (OPVEE) with intranasal naloxone, was published in the Journal of Clinical Pharmacology.
The study met its primary endpoint by showing that OPVEE reversed respiratory depression within five minutes of administration, while naloxone took 20 minutes to achieve a similar effect. Minute ventilation, a measure of breathing, reached approximately 95% of the pre-opioid baseline within five minutes after OPVEE was administered.
In the study, 69 healthy volunteers experienced a reduction in minute ventilation after being administered remifentanil, a synthetic opioid. They were then treated with either OPVEE or naloxone. OPVEE was found to be non-inferior and superior to naloxone in the speed of reversing opioid-induced respiratory depression.
OPVEE shows rapid reversal of opioid effects in study
OPVEE shows rapid reversal of opioid effects in study
Investing.com | Editor Brando Bricchi
Published Mar 11, 2024 18:52
Be the first to comment
OPVEE shows rapid reversal of opioid effects in study
RICHMOND, Va. - Indivior PLC (LSE/Nasdaq: LON:INDV) has announced the results of a pharmacodynamic study indicating that its drug OPVEE® can quickly reverse opioid-induced respiratory depression, a major cause of death in opioid overdoses. The study, comparing intranasal nalmefene (OPVEE) with intranasal naloxone, was published in the Journal of Clinical Pharmacology.
The study met its primary endpoint by showing that OPVEE reversed respiratory depression within five minutes of administration, while naloxone took 20 minutes to achieve a similar effect. Minute ventilation, a measure of breathing, reached approximately 95% of the pre-opioid baseline within five minutes after OPVEE was administered.
In the study, 69 healthy volunteers experienced a reduction in minute ventilation after being administered remifentanil, a synthetic opioid. They were then treated with either OPVEE or naloxone. OPVEE was found to be non-inferior and superior to naloxone in the speed of reversing opioid-induced respiratory depression.
ADVERTISEMENT
Although adverse events were reported in over 90% of subjects following both drugs, these were mostly mild to moderate and were attributed to the remifentanil and experimental conditions rather than the drugs themselves. Common adverse events included headache, nausea, vomiting, and dizziness.
Get The App
Join the millions of people who stay on top of global financial markets with Investing.com.
Download Now
The urgency for rapid-acting opioid reversal agents is underscored by the high number of opioid overdose deaths, which in the United States totaled over 80,000 in the 12 months ending in September 2023, with synthetic opioid
Article from Investing.com (Published Mar 11, 2024 18:52)
https://uk.investing.com/news/stock-market-news/opvee-shows-rapid-reversal-of-opioid-effects-in-study-93CH-3376280
I will take my prediction back from yesterday as £18 quite possibe today with thus game changing news
Started: dmkingy, 11 Mar 2024 14:51
Last post: Tango-Cash, 11 Mar 2024 15:09
A bit of profit taking by the Directors, nothing to worry about and certainly no concerning news otherwise it would be tantamount to insider trading which is of course illegal. Of course it's not ideal when Directors sell but they've only top sliced and still have significant holdings so onwards and upwards from here. My target is still £18 in the short term, and hoping it hits that by March end.
Big drop since the Directors/PDMR sells which is frustrating. How low is this going? 😞
Started: Apeirogon, 4 Mar 2024 08:39
Last post: dodgepot, 4 Mar 2024 09:16
No idea, been surfing to see any news, but nothing !!
Has to be a big sell waiting in the wings over the weekend.
It has made a comeback in the last hour…but obviously still down…
Anyone know what caused the -6% drop at the open ?
Started: Tango-Cash, 29 Feb 2024 07:24
Last post: Tango-Cash, 29 Feb 2024 07:24
LAST RNS 22 February 2024: Following the above transaction and cancellation of the purchased shares, Indivior has 135,272,708 ordinary shares with voting rights in issue.
Today's RNS : Following the above transaction and cancellation of the purchased shares, Indivior has 136,490,175 ordinary shares with voting rights in issue.
How on earth has the outstanding company shares total jumped up by 1.22 million shares?
One to send to I.R. because it is not correct.
Started: Tango-Cash, 26 Feb 2024 14:25
Last post: idkmybffjill, 26 Feb 2024 14:42
They have only spent $42 million so far.
Is the company share buy back declared on 17 November 2023 complete? There has been no RNS for the last 2 business days in respect to the same.
Started: Evertheoptimism, 22 Feb 2024 14:47
Last post: eviking, 22 Feb 2024 23:28
For a start saving 23pc I am a fan !
List in us is a great move most sharholders already 70pc versus 30pc here
Looks like US likes INDV, it is up 24% now,excellent
Sadly but inevitably the only way forward for iNDV to reach its full potential and achieve full shareholder value is to make the companies listing primarily in the USA, massive unjustified divide between the two bourses, UK Plc being kept/played artificially low to enable potential US takeovers at ridiculously low levels just look at the likes of BT, VOD LLOY etc etc great businesses but on the wrong bourse imo I for one will be giving it the thumbs up when asked to vote on the switch, lovely rise today which I expected after Tuesdays shenanigans just proves my point
Started: BetterX, 22 Feb 2024 09:18
Last post: idkmybffjill, 22 Feb 2024 09:55
All pharma has endless stream of litigation.
Worst case if multiple never goes up, they can keep buying cheap shares.
It looks looks like a strong buy until you read note 13 re. legal proceedings. It'll never trade at a decent multiple given the seemingly endless stream of litigation... Nevertheless, a nice trade this morning and good luck to those who hold for the US listing...
INDV continues to storm ahead despite increased competition. The SP was far too low so today's price increase is just partial catch-up. The switch to US main listing is a good move & will generate a lot more interest from US based investors. The big questions are how much longer will INDV remain independent before big PHARMA swallows it and at what price? To answer my own questions, not that long & North of £25.
Started: Tango-Cash, 22 Feb 2024 07:41
Last post: dodgepot, 22 Feb 2024 09:25
Well must admit those numbers far exceeded my expectations…
Was hopeful, but too many times there has been a dampener put on the reports, not this time..
Cracking average I'm at 8.18
Looking forward;
FY 2024
Net Revenue (NR)1
$1,240m to $1,330m
(+18% at midpoint vs. FY 2023)
Yes, very nice. 17% up shortly after opening.
Another USD100m buyback and 18% net revenue guidance for 2024. Would like a dividend quite soon.
Very glad I topped up at £11.68 in December and £12.21 in January, taking my average up to £7.35.
Woo hoo!
Started: brigg, 22 Feb 2024 08:35
Last post: brigg, 22 Feb 2024 08:35
Hopefully back up to the £20 mark
Started: Darnitagain, 21 Feb 2024 19:12
Last post: Cashola, 21 Feb 2024 22:18
Th erns is usually the day following purchase, save for Friday which appears on the Monday.
The share buyback has been ongoing for a while, as pointed out by TC. They did one previously and also had, from memory a share consolidation. The shares are purchased off four exchanges. The shares are literally wiped out and not kept in the treasury for the staff. It has, in theory, the effect of enlarging the eps and the sp. My thoughts are that we are in effect below the sp prior to share consolidation but we have had a litigation hit or two along with some money going out. Results tomorrow. I hope the buyback continues.
Indivior PLC announces an Equity Buyback for 13,631,504 shares, for $100 million. Indivior PLC (LSE:INDV) announces a share repurchase program. Under the program, the company will repurchase up to 13,631,504 shares for $100 million worth of shares. The purpose of the program is to reduce share capital of the company. (17 Nov 2023).
Anyone care to opine re the following as it appears the vol. is reflected in the share count in the US today. INDIVIOR PLC ("Indivior") announces that on February 20, 2024, it purchased for cancellation the following number of its ordinary shares of $0.50 each through Morgan Stanley & Co. International Plc.
Ordinary Shares
Date of purchases:
February 20, 2024
Number of ordinary shares purchased:
33,635
Highest Price per share:
1,350.00
Lowest Price per share:
1,322.00
Volume Weighted Average Price per share:
1,334.32
Nearly a 9% drop in the last few days. Is this in preparation of the results? Hope not.
Started: Tango-Cash, 12 Feb 2024 13:44
Last post: Tango-Cash, 12 Feb 2024 13:44
Share price has just taken off to 1431p with a massive 334k buy at 13:33hrs. Nice jump!
No doubt loading up before results in 10 days - 22 February 2024.
Could see 1600p+ post results.
Started: Tango-Cash, 30 Jan 2024 20:31
Last post: idkmybffjill, 1 Feb 2024 19:58
Thank you for sharing. I think the misleading prescription data + the larger than expected legal settlement are what’s keeping us down here.
Indivior has issues but it’s still too cheap, says BlackRock Throgmorton
BlackRock manager Dan Whitestone believes Indivior (INDV) shares are too cheap despite legal and competition concerns.
Whitestone holds the pharmaceutical group, which specialises in opioid addiction treatments, in his £584m BlackRock Throgmorton (THRG) closed-ended investment trust.
The shares in the group have been weak recently following the slightly higher cost of settling the bulk of its outstanding legal issues.
‘With continued strong trading in the core and regulatory risk in the rear-view mirror, we are frustrated by the performance of the shares which have been impacted by a few factors in recent months,’ said Whitestone.
This includes ‘a poorly-explained acquisition’ that saw it insource some manufacturing, ‘some higher-than expected selling general, and administrative costs’, and the launch of a competitor product and some weaker prescription data.
‘The first two we are less concerned about and think represents management sensibly investing some of the earnings beats into strengthening the business,’ said Whitestone.
‘We are keeping a closer eye on the prescription data and the competitor and have discussed both at length with management.’
The shares, which were at £13.74 on Monday, are ‘too cheap’, the manager added, pointing out they are trading at under 10x price/earnings and a double-digit percentage of its market cap is in net cash.
(P.S. Holding this time for £18.00. Not bothered if it takes 6-12 months . I admit I sold at the wrong time previously. Yes frustrating!).
Started: mythyaar, 21 Dec 2023 09:55
Last post: Avicenna2, 25 Jan 2024 17:12
Balyasny seems to have reduced short to 0.39% on 23 jan 2024
We also have pros who own 10% of the company. Why are only the short sellers correct? And where are you finding the info that Balyasny is short?
Institutional investors should of course read "private investors"!!
By Balyasny Asset Management of 0.62%. So we now have 1.15% of Indivior's stock in the hands of shorters.
So, that's two very well funded, very experienced investment firms betting against Indivior.
And in Balyasny's case, they're prepared to short it at the current SP - so they clearly think there's significant leeway (decline) to come yet, for them to make a killing.
Let's not kid ourselves as institutional investors that we know anything significant about this stock. And let's not be naive to think that the research and intel that the current shorters have on Indivior are anything but a factor of 100 times greater than what we know.
I really hope I'm wrong, but when the pros are wading in and shorting at the current price, the canary in the coal mine has long since expired.
Started: JBUS, 24 Jan 2024 16:04
Last post: HumpyDumpy, 24 Jan 2024 22:21
Don’t blame the lawyers. Blame the clients! Anyway, yes, huge potential. This has been a rollercoaster ride, and it’s been coasting down for far too long. Just needed a little momentum the other way. The positives here have been disregarded for too long. Well overdue a serious rerate. I’ve been here for some time. Was my rocket ship for quite some time. Has stalled a bit, but all the fundamentals are there to get us back into orbit.
This is my top pick this year. Single digit PE, buckets of cash and more than a shadow of litigation.
Good luck to addicts proving they got gum disease from INDV and not what got them there in the first place. How many of these have regular dental records. Exactly. Don't blame the lawyers for trying, this has been a punch bag for a long time but they should be okay this time.
What is the biggest killer in the US today of 18 to 45 year olds? Fentanyl. https://www.getsmartaboutdrugs.gov/media/dea-administrator-record-fentanyl-overdose-deaths
It is very sad, but this is indeed a growth industry and a growth stock on a single digit PE.
For all the bluster about Covid and huge amounts of money thrown at the problem, drug related deaths are and were significantly greater today and through the worst Covid years
Don't be frightened of the lawyers, scumbags indeed but just making a living like the Fentanyl dealers.
Still certain corners of the press (and shorts) pose INDV as the bad guy!
Truth will out.
Started: avicenna110, 7 Jan 2024 13:49
Last post: dedino, 23 Jan 2024 09:37
Investors chronicle view:
Despite having a slim portfolio of drugs, pharmaceutical group Indivior (INDV) is reasonably confident about future sales growth. This is because most of its medicines treat one increasingly prevalent condition in North American markets: opioid use disorder.
Article in Sunday Times today
Top taker picks by analysts of Quest
mentions INDV as target for takeover for 2024
amongst others